Hangzhou Tigermed Consulting Total Liabilities
Hangzhou Tigermed Consulting total liabilities. Based on the latest financial reports, Hangzhou Tigermed Consulting (300347) has total liabilities worth CN¥4.24 Billion CNY (≈ $619.80 Million USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check 300347 financial resilience to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Hangzhou Tigermed Consulting (2009–2025)
Total liabilities of Hangzhou Tigermed Consulting from 2009 to 2025. This chart illustrates how Hangzhou Tigermed Consulting's total liabilities have evolved over time, based on quarterly financial data. Explore Hangzhou Tigermed Consulting (300347) long-term investment share to see how much of total assets are deployed in long-term investments.
Hangzhou Tigermed Consulting Competitors by Total Liabilities
The table below lists competitors of Hangzhou Tigermed Consulting ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Engie Brasil Energia S.A
F:7TE1
|
Germany | €43.90 Billion |
|
Gerdau SA ADR
NYSE:GGB
|
USA | $28.24 Billion |
|
Bachem Holding AG
SW:BANB
|
Switzerland | CHF650.41 Million |
|
Yunnan Chihong Zinc&Germanium Co Ltd
SHG:600497
|
China | CN¥7.60 Billion |
|
Guobo Electronics Co. Ltd. A
SHG:688375
|
China | CN¥1.95 Billion |
|
Blackstone Secured Lending Fund
NYSE:BXSL
|
USA | $7.85 Billion |
|
CG Oncology, Inc. Common stock
NASDAQ:CGON
|
USA | $38.99 Million |
|
GREEK O.FOOTB. ADR 1/2
F:GF8A
|
Germany | €1.75 Billion |
Liability Composition Analysis (2009–2025)
This chart breaks down Hangzhou Tigermed Consulting's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Hangzhou Tigermed Consulting total assets.
Liquidity & Leverage Metrics
Hangzhou Tigermed Consulting Total Liabilities Ratios Explained
Hangzhou Tigermed Consulting total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.30 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.20 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.15 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Hangzhou Tigermed Consulting's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Hangzhou Tigermed Consulting (2009–2025)
The table below shows the annual total liabilities of Hangzhou Tigermed Consulting from 2009 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | CN¥4.10 Billion ≈ $600.31 Million |
-10.94% |
| 2024-12-31 | CN¥4.61 Billion ≈ $674.08 Million |
-11.87% |
| 2023-12-31 | CN¥5.23 Billion ≈ $764.90 Million |
+9.69% |
| 2022-12-31 | CN¥4.77 Billion ≈ $697.34 Million |
+51.96% |
| 2021-12-31 | CN¥3.14 Billion ≈ $458.89 Million |
+90.34% |
| 2020-12-31 | CN¥1.65 Billion ≈ $241.09 Million |
-19.50% |
| 2019-12-31 | CN¥2.05 Billion ≈ $299.50 Million |
+45.59% |
| 2018-12-31 | CN¥1.41 Billion ≈ $205.72 Million |
+79.81% |
| 2017-12-31 | CN¥781.85 Million ≈ $114.41 Million |
+42.53% |
| 2016-12-31 | CN¥548.54 Million ≈ $80.27 Million |
+0.81% |
| 2015-12-31 | CN¥544.12 Million ≈ $79.62 Million |
+23.46% |
| 2014-12-31 | CN¥440.72 Million ≈ $64.49 Million |
+733.66% |
| 2013-12-31 | CN¥52.87 Million ≈ $7.74 Million |
+37.24% |
| 2012-12-31 | CN¥38.52 Million ≈ $5.64 Million |
-5.43% |
| 2011-12-31 | CN¥40.73 Million ≈ $5.96 Million |
+68.85% |
| 2010-12-31 | CN¥24.12 Million ≈ $3.53 Million |
+4.29% |
| 2009-12-31 | CN¥23.13 Million ≈ $3.38 Million |
-- |
About Hangzhou Tigermed Consulting
Hangzhou Tigermed Consulting Co., Ltd, together with its subsidiaries, provides contract research organization services in the People's Republic of China and internationally. The company offers clinical trial operation services, such as clinical pharmacology, registration and regulatory affairs, scientific affairs, medical translation, pharmacovigilance, real-world research, third-party auditing … Read more